SIFAR
Last board
2 directors, 1 auditor, last change in 2022Statutory auditor, permanent representative Sébastien Schueremans
appointed by deed of 23-05-2024
Mandates through the years
5 names, the dashed line is todayCaroline Vancoillie
Director
Director
Dominique Lecocq
Director
Director
Mazars Bedrijfsrevisoren - Réviseurs d'Entreprises BV/SRL
Statutory auditor
Statutory auditor
Forvis Mazars Réviseurs d’Entreprises
Statutory auditor
Statutory auditor
Thomas Debeys
Director
Director
BoardEarlier
Mandates as a list
- Caroline Vancoillie
- Director, from 27-04-2021 to date
- Dominique Lecocq
- Director, from 27-04-2021 to date
- Mazars Bedrijfsrevisoren - Réviseurs d'Entreprises BV/SRL
- Statutory auditor, from 27-04-2021 to date
- Forvis Mazars Réviseurs d’Entreprises
- Statutory auditor, from 27-04-2021 to 23-05-2024
- Thomas Debeys
- Director, from 07-05-2019 to 30-06-2022
Control
Consolidating parent
Equity €9.16bn
Profit €383.4m in 2025 (profit €389.6m in 2024)
Source: parent in own accounts 2023
consolidates
This company
SIFAR
Equity €87,831
Loss €1,828 in 2023
Capital
- Capital
- €62,500
- Shares
- 100
- Contribution per share
- €625
- Equity per share
- €878 in 2023
- Source
- 2023 annual accounts
Owners through the years
as the annual accounts name themOwners as a list
- UCB PHARMA
- UCB Fipar
- U C B
- UCB FINANCE NV
Source: shareholder structure in its own accounts, parent in its own accounts